iPS Cells & Regenerative Medicine Weekly Report August 2, 2026

iPS Cells & Regenerative Medicine Weekly Report August 16, 2026

PTC Therapeutics and Eli Lilly to Acquire Sangamo Assets for Up to $264M in Bankruptcy Auction, Bolstering Rare Disease Pipelines

Precision and Pace: Liv Hospital Details Step-by-Step Innovations in CAR-T Cell Manufacturing

Overcoming Raw Material Variability Challenges for Autologous Adoptive Cell Therapies: Risk-Based Control and Decentralized Manufacturing

Merck Expands Singapore BioReliance Lab with Asia Pacific’s First Cell Line Characterization and GMP NGS Capabilities

China’s Hopstem Biotech Secures Nearly RMB 200 Million in Series C First Close to Advance iPSC Cell Therapy Pipeline Led by hNPC01

XsellSmart Biopharmaceutical Completes Patient Enrollment in Phase 1 Trial for Universal Cell Therapy XS411 in Parkinson’s-Type Multiple System Atrophy

Chronic Exposure to Chlorate at Regulatory Safety Limits Induces p21/p16-Mediated Neuronal Senescence and Parkinsonian Decline in iPSC-Derived Neurons